RESEARCH ARTICLE
Withdrawal-Emergent Dyskinesias following Varenicline Therapy
Brittany A Toffey, Marcie Rabin , Roger Kurlan*
Article Information
Identifiers and Pagination:
Year: 2015Volume: 9
First Page: 7
Last Page: 8
Publisher ID: TONEUJ-9-7
DOI: 10.2174/1874205X01509010007
Article History:
Received Date: 10/1/2014Revision Received Date: 24/3/2014
Acceptance Date: 25/3/2014
Electronic publication date: 8/6/2015
Collection year: 2015

open-access license: This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/)
Abstract
Varenicline (Chantix[R]) is a nicotinic acetylcholine receptor partial agonist used to aid smoking cessation. Adverse psychiatric and behavioral effects of the drug are recognized and national drug monitoring has included reports of tardive dyskinesia, but no cases have been described in the literature. We now report the first two cases of varenicline-related withdrawal emergent dyskinesias.